📊 CBLL Key Takeaways
Is Ceribell, Inc. (CBLL) a Good Investment?
Ceribell exhibits strong revenue growth (+36.1% YoY) with exceptional gross margins (87.9%), indicating solid market demand and pricing power in the electromedical device sector. However, the company is unprofitable at the operating level (-65.6% margin) with significant cash burn (-$41.6M FCF), and without clear visibility to profitability, the company is consuming cash reserves despite strong balance sheet liquidity. The divergence between revenue growth and operating losses suggests execution challenges or heavy investment phase, requiring demonstrated progress toward profitability within 12-18 months to validate the business model.
Ceribell shows strong top-line momentum and exceptional gross margins, suggesting a differentiated product with real commercial traction. However, the business is still deeply unprofitable, with very negative operating margins and heavy cash burn, so the fundamental story depends on whether revenue growth can translate into meaningful operating leverage before cash consumption becomes a larger issue.
Why Buy Ceribell, Inc. Stock? CBLL Key Strengths
- Strong revenue growth of 36.1% YoY indicating market traction and demand
- Exceptional gross margin of 87.9% demonstrating pricing power and operational efficiency at manufacturing level
- Fortress balance sheet with $40.5M cash, 9.73x current ratio, and zero debt providing runway for operations
- Revenue growth of 36.1% YoY indicates strong demand and commercial expansion
- Gross margin of 87.9% suggests attractive unit economics and pricing power
- Very strong liquidity and no long-term debt provide balance-sheet flexibility while scaling
CBLL Stock Risks: Ceribell, Inc. Investment Risks
- Severe operating losses (-$65.6% margin) with negative net income of -$53.4M indicating unsustainable unit economics
- Significant cash burn of -$41.6M in FCF despite positive revenue, depleting cash reserves at current burn rate within ~1 year
- Heavy opex structure relative to revenue suggests sales, R&D, or administrative costs are not scaling with gross profit growth
- No visibility to path to profitability with continued negative operating cash flow and operating margin deterioration risk
- Operating margin of -65.6% shows the cost structure remains far from sustainable
- Free cash flow of -$41.58M means the company is still consuming substantial cash
- Net losses remain large relative to revenue, creating execution risk if growth slows
Key Metrics to Watch
- Operating margin trajectory and path to breakeven (target: positive operating income within 4 quarters)
- Operating cash flow and free cash flow burn rate (critical: must improve toward positive FCF)
- Gross margin sustainability and operating expense growth rate relative to revenue growth acceleration
- Cash runway and burn rate (at current burn: ~1 year of operations remaining with $40.5M cash)
- Operating margin improvement versus revenue growth
- Free cash flow burn and ending cash balance
Ceribell, Inc. (CBLL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.73x current ratio provides a solid financial cushion.
CBLL Profit Margin, ROE & Profitability Analysis
CBLL vs Healthcare Sector: How Ceribell, Inc. Compares
How Ceribell, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ceribell, Inc. Stock Overvalued? CBLL Valuation Analysis 2026
Based on fundamental analysis, Ceribell, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ceribell, Inc. Balance Sheet: CBLL Debt, Cash & Liquidity
CBLL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ceribell, Inc.'s revenue has grown significantly by 36% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.39 indicates the company is currently unprofitable.
CBLL Revenue Growth, EPS Growth & YoY Performance
CBLL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $17.2M | -$8.5M | $-0.37 |
| Q2 2025 | $15.3M | -$8.5M | $-0.38 |
| Q1 2025 | $14.4M | -$8.5M | $-0.36 |
| Q3 2024 | $11.6M | -$6.2M | $-1.32 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ceribell, Inc. Dividends, Buybacks & Capital Allocation
CBLL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ceribell, Inc. (CIK: 0001861107)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CBLL
What is the AI rating for CBLL?
Ceribell, Inc. (CBLL) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CBLL's key strengths?
Claude: Strong revenue growth of 36.1% YoY indicating market traction and demand. Exceptional gross margin of 87.9% demonstrating pricing power and operational efficiency at manufacturing level. ChatGPT: Revenue growth of 36.1% YoY indicates strong demand and commercial expansion. Gross margin of 87.9% suggests attractive unit economics and pricing power.
What are the risks of investing in CBLL?
Claude: Severe operating losses (-$65.6% margin) with negative net income of -$53.4M indicating unsustainable unit economics. Significant cash burn of -$41.6M in FCF despite positive revenue, depleting cash reserves at current burn rate within ~1 year. ChatGPT: Operating margin of -65.6% shows the cost structure remains far from sustainable. Free cash flow of -$41.58M means the company is still consuming substantial cash.
What is CBLL's revenue and growth?
Ceribell, Inc. reported revenue of $89.1M.
Does CBLL pay dividends?
Ceribell, Inc. does not currently pay dividends.
Where can I find CBLL SEC filings?
Official SEC filings for Ceribell, Inc. (CIK: 0001861107) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CBLL's EPS?
Ceribell, Inc. has a diluted EPS of $-1.46.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CBLL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ceribell, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CBLL stock overvalued or undervalued?
Valuation metrics for CBLL: ROE of -34.4% (sector avg: 15%), net margin of -60.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CBLL stock in 2026?
Our dual AI analysis gives Ceribell, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CBLL's free cash flow?
Ceribell, Inc.'s operating cash flow is $-40.8M, with capital expenditures of $767.0K. FCF margin is -46.7%.
How does CBLL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -60.0% (avg: 12%), ROE -34.4% (avg: 15%), current ratio 9.73 (avg: 2).